

=> d his

(FILE 'HOME' ENTERED AT 18:28:32 ON 13 JUN 2004)

FILE 'MEDLINE, BIOSIS' ENTERED AT 18:28:48 ON 13 JUN 2004

L1	0 S PRO7170
L2	3446 S GLUCOSE (L) FATTY ACID? (L) UPTAKE
L3	17962 S (GLUCOSE OR FATTY ACID?) (W) UPTAKE
L4	468 S GLUCOSE (L) FATTY ACID? (L) UPTAKE (L) SKELETAL MUSCLE
L5	277 DUP REM L4 (191 DUPLICATES REMOVED)
L6	238 S L5 AND PY<2003
L7	386 S (ASHKENAZI, A?)/AU
L8	0 S L6 AND L7
L9	0 S EXMAD

XX PRO polynucleotides used to produce polypeptides used to target
PT bioactive molecules such as toxins, radiolabels or antibodies, to
PT specific cells, to cause targeted cell death -
XX
PS Claim 12; Fig 326; 935pp; English.
XX
CC The present invention describes human secreted and transmembrane PRO
CC proteins. The PRO proteins have cytotatic activity. The PRO proteins
CC can be used for targeted delivery of bioactive molecules, such as
CC toxins, radiolabels or antibodies, that cause cell death. PRO nucleotide
CC sequences, and their fragments, can be used as hybridisation probes, in
CC chromosomal and gene mapping, and in the generation of anti-sense RNA
CC and DNA. They may also be used to produce transgenic animals which are
CC used to develop and screen therapeutically useful reagents. The PRO
CC nucleotide and protein sequence can be used for tissue typing and in
CC treating cancer. Anti-PRO antibodies can be used in diagnostic assays.
CC AAF44270 to AAF44470 represent PCR primers and hybridisation probes used
CC in the isolation of human PRO sequences. AAF44087 to AAF44269 and
CC AAB65154 to AAB65300 represent human PRO polynucleotide and protein
CC sequences given in the exemplification of the present invention.
XX
SQ Sequence 482 AA;

Query Match 100.0%; Score 2429; DB 22; Length 482;
Best Local Similarity 100.0%; Pred. No. 1e-148;
Matches 482; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 MGCLWGLALPLFFFCWEVGVSGSAGSTRADTAMTDDTEVPAMTLPAGHALETQTL 60
Db 1 MGCLWGLALPLFFFCWEVGVSGSAGSTRADTAMTDDTEVPAMTLPAGHALETQTL 60
QY 61 SAETSSRASTPAGPIPEAETRGAKRISPARETRSFTKTSNFMVLIATSVETSAAGSPE 120
Db 61 SAETSSRASTPAGPIPEAETRGAKRISPARETRSFTKTSNFMVLIATSVETSAAGSPE 120
QY 121 GAGMTTQTITGSDPEEAIPTDCTDSSBEAKTLMDIILTAHTSTEAKGLSESSASS 180
Db 121 GAGMTTQTITGSDPEEAIPTDCTDSSBEAKTLMDIILTAHTSTEAKGLSESSASS 180
QY 181 DGHPVITPSRASESSASSDGPHPVITPSRASESSASSDGPHPVITPSRASESSASS 240
Db 181 DGHPVITPSRASESSASSDGPHPVITPSRASESSASSDGPHPVITPSRASESSASS 240
QY 241 ALVTVTNIEVINCSTIETITSSIPGASDIDLIPTGKASSTSDPPALPDSTEAKPHI 300
Db 241 ALVTVTNIEVINCSTIETITSSIPGASDIDLIPTGKASSTSDPPALPDSTEAKPHI 300
QY 301 TEVTASAEITLSTAGTTESAAPHATVGTPLTNSATEREVTAPGATTLSGALVTVSRNPLE 360
Db 301 TEVTASAEITLSTAGTTESAAPHATVGTPLTNSATEREVTAPGATTLSGALVTVSRNPLE 360
QY 361 ETGALSVEITSYKVGAAVSVIEAGAVKTTSPAGSSASSYSPSEALKKNFTSETPT 420
Db 361 ETGALSVEITSYKVGAAVSVIEAGAVKTTSPAGSSASSYSPSEALKKNFTSETPT 420
QY 421 MDIATKGPFTSDPLPSVPTTNSRGNTSLAKITTSKTKMPQPRPLPGRGP 480
Db 421 MDIATKGPFTSDPLPSVPTTNSRGNTSLAKITTSKTKMPQPRPLPGRGP 480
QY 481 QT 482
Db 481 QT 482

RESULT 4
ID AAB27225
AC AAB27225;
DT 27-MAR-2001 (first entry)
XX

The Jan

DE Human EXMAD-3 SEQ ID NO: 3.
XX Extracellular matrix and adhesion-associated protein; EXMAD; cancer;
KW inflammation; reproductive disorder; cardiovascular disorder;
KW immune disorder; musculoskeletal disorder; developmental disorder;
KW gastrointestinal disorder; cell proliferation disorder.
XX
OS Homo sapiens.
XX
FN WO200068380-A2.
XX
PD 16-NOV-2000.
XX
PF 10-MAY-2000; 2000WO-US12811.
XX
PR 11-MAY-1999; 99US-0133643.
PR 23-AUG-1999; 99US-0150409.
XX
PA (INCY-) INCYTE GENOMICS INC.
XX
PI Bandman O, Hillman JL, Tang YT, Lal P, Yue H, Baughn MR, Lu DAM;
PI Azimzai Y;
XX
DR WPI; 2001-007395/01.
DR N-PSDB; AAC66892.
XX
PT Isolated polynucleotide encoding extracellular matrix or
PT adhesion-associated protein (EXMAD) useful for diagnosing, treating, or
PT preventing disorders associated with expression of EXMAD such as
PT proliferative, immune and genetic disorders -
XX
PS Claim 1; Page 89-90; 129pp; English.
XX
CC The present invention provides the protein and coding sequences for 25
CC novel extracellular matrix and adhesion-associated proteins (EXMADS).
CC These are designated EXMAD-1, EXMAD-2, EXMAD-3, EXMAD-4, EXMAD-5,
CC EXMAD-6, EXMAD-7, EXMAD-8, EXMAD-9, EXMAD-10, EXMAD-11, EXMAD-12,
CC EXMAD-13, EXMAD-14, EXMAD-15, EXMAD-16, EXMAD-17, EXMAD-18, EXMAD-19,
CC EXMAD-20, EXMAD-21, EXMAD-22, EXMAD-23, EXMAD-24 and EXMAD-25. They are
CC useful in the prevention and treatment of cancers, cell proliferation,
CC cardiovascular, reproductive, immune, musculoskeletal, developmental and
CC gastrointestinal disorders and inflammation.
XX
SQ Sequence 482 AA;

Query Match 100.0%; Score 2429; DB 22; Length 482;
Best Local Similarity 100.0%; Pred. No. 1e-148;
Matches 482; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 MGCLWGLALPLFFFCWEVGVSGSAGSTRADTAMTDDTEVPAMTLPAGHALETQTL 60
Db 1 MGCLWGLALPLFFFCWEVGVSGSAGSTRADTAMTDDTEVPAMTLPAGHALETQTL 60
QY 61 SAETSSRASTPAGPIPEAETRGAKRISPARETRSFTKTSNFMVLIATSVETSAAGSPE 120
Db 61 SAETSSRASTPAGPIPEAETRGAKRISPARETRSFTKTSNFMVLIATSVETSAAGSPE 120
QY 121 GAGMTTQTITGSDPEEAIPTDCTDSSBEAKTLMDIILTAHTSTEAKGLSESSASS 180
Db 121 GAGMTTQTITGSDPEEAIPTDCTDSSBEAKTLMDIILTAHTSTEAKGLSESSASS 180
QY 181 DGHPVITPSRASESSASSDGPHPVITPSRASESSASSDGPHPVITPSRASESSASS 240
Db 181 DGHPVITPSRASESSASSDGPHPVITPSRASESSASSDGPHPVITPSRASESSASS 240
QY 241 ALVTVTNIEVINCSTIETITSSIPGASDIDLIPTGKASSTSDPPALPDSTEAKPHI 300
Db 241 ALVTVTNIEVINCSTIETITSSIPGASDIDLIPTGKASSTSDPPALPDSTEAKPHI 300
QY 301 TEVTASAEITLSTAGTTESAAPHATVGTPLTNSATEREVTAPGATTLSGALVTVSRNPLE 360
Db 301 TEVTASAEITLSTAGTTESAAPHATVGTPLTNSATEREVTAPGATTLSGALVTVSRNPLE 360

QY 361 ETSALSVETESVYKVSIGAPVSIIEAGSVGKTTSPAGSSASSYSPSEAAKNFTPTSETPT 420
 Db 361 ETSALSVETESVYKVSIGAPVSIIEAGSVGKTTSPAGSSASSYSPSEAAKNFTPTSETPT 420
 QY 421 MDIATKGFPTSRDPLSPVPTTNSRGNTSLAKITTSARTMKPQPPRLPGRGRP 480
 Db 421 MDIATKGFPTSRDPLSPVPTTNSRGNTSLAKITTSARTMKPQPPRLPGRGRP 480
 QY 481 QT 482
 Db 481 QT 482

RESULT 5
 ID ABU72052
 XX ABU72052 standard; Protein; 482 AA.
 AC ABU72052;
 XX
 DT 11-JUN-2003 (first entry)
 XX
 DE Novel human secreted and transmembrane protein PRO7170.
 XX
 KW Human; secreted and transmembrane polypeptide; PRO;
 KW fibroblast growth factor receptor; PRO533; PRO301; PRO187; PRO337;
 KW PRO411; PRO10096; PRO246; PRO6307; PRO6003; FGFR-3; FGFR-4; FGFR-1;
 KW FGFR-2; PRO6004; PRO4356; PRO2630; PRO265; PRO951; bioactive molecule;
 KW toxin; radiolabel; antibody; cell death; chromosome mapping;
 KW gene mapping; transgenic animal; knockout animal; gene therapy;
 KW tissue typing.
 XX
 OS Homo sapiens.
 XX
 PN US2002177165-A1.
 XX
 PD 28-NOV-2002.
 XX
 PF 01-FEB-2002; 2002US-0066500.
 XX
 PR 14-JUL-1998; 98WO-US14552.
 PR 10-SEP-1998; 98WO-US18824.
 PR 14-SEP-1998; 98WO-US19093.
 PR 16-SEP-1998; 98WO-US19330.
 PR 17-SEP-1998; 98WO-US19437.
 PR 20-NOV-1998; 98WO-US24855.
 PR 25-NOV-1998; 98WO-US25190.
 PR 01-DEC-1998; 98WO-US25108.
 PR 08-MAR-1999; 99WO-US05028.
 PR 02-JUN-1999; 99WO-US12252.
 PR 01-SEP-1999; 99WO-US20111.
 PR 08-SEP-1999; 99WO-US20594.
 PR 15-SEP-1999; 99WO-US21090.
 PR 30-SEP-1999; 99WO-US21547.
 PR 10-NOV-1999; 99WO-US28313.
 PR 01-DEC-1999; 99WO-US28301.
 PR 02-DEC-1999; 99WO-US28565.
 PR 20-DEC-1999; 99WO-US30399.
 PR 05-JAN-2000; 2000WO-US00219.
 PR 18-FEB-2000; 2000WO-US04341.
 PR 18-FEB-2000; 2000WO-US04342.
 PR 22-FEB-2000; 2000WO-US04414.
 PR 01-MAR-2000; 2000WO-US05601.
 PR 02-MAR-2000; 2000WO-US05841.
 PR 09-MAR-2000; 2000WO-US06471.
 PR 20-MAR-2000; 2000WO-US07377.
 PR 30-MAR-2000; 2000WO-US08439.
 PR 15-MAY-2000; 2000WO-US13358.
 PR 17-MAY-2000; 2000WO-US13705.
 PR 22-MAY-2000; 2000WO-US14042.
 PR 30-MAY-2000; 2000WO-US14941.
 PR 02-JUN-2000; 2000WO-US15264.
 PR 11-AUG-2000; 2000WO-US22031.
 PR 23-AUG-2000; 2000WO-US23522.

PR 24-AUG-2000; 2000WO-US23328.
 PR 01-DEC-2000; 2000WO-US23678.
 PR 28-FEB-2001; 2001WO-US06520.
 PR 30-MAY-2001; 2001WO-US17443.
 PR 01-JUN-2001; 2001WO-US17800.
 PR 20-JUN-2001; 2001WO-US19692.
 PR 29-JUN-2001; 2001WO-US21066.
 PR 09-JUL-2001; 2001WO-US21735.
 PR 26-AUG-1997; 97US-056974P.
 PR 17-SEP-1997; 97US-059115P.
 PR 18-SEP-1997; 97US-059283P.
 PR 19-SEP-1997; 97US-059588P.
 PR 17-OCT-1997; 97US-062285P.
 PR 24-OCT-1997; 97US-062816P.
 PR 24-OCT-1997; 97US-0633082P.
 PR 27-OCT-1997; 97US-063329P.
 PR 29-OCT-1997; 97US-063733P.
 PR 21-NOV-1997; 97US-066364P.
 PR 25-NOV-1997; 97US-066840P.
 PR 16-DEC-1997; 97US-069694P.
 PR 09-FEB-1998; 98US-074086P.
 PR 09-FEB-1998; 98US-0740932P.
 PR 25-MAR-1998; 98US-079294P.
 PR 08-APR-1998; 98US-081049P.
 PR 10-AUG-1998; 98US-095998P.
 PR 18-AUG-1998; 98US-097000P.
 PR 09-SEP-1998; 98US-099601P.
 PR 10-SEP-1998; 98US-099803P.
 PR 10-SEP-1998; 98US-099811P.
 PR 10-SEP-1998; 98US-099812P.
 PR 17-SEP-1998; 98US-100858P.
 PR 24-SEP-1998; 98US-101922P.
 PR 28-OCT-1998; 98US-106032P.
 PR 20-NOV-1998; 98US-109304P.
 PR 23-MAR-1999; 99US-125778P.
 PR 15-JUN-1999; 99US-139695P.
 PR 20-JUL-1999; 99US-145070P.
 PR 26-JUL-1999; 99US-145698P.
 PR 17-AUG-1999; 99US-149396P.
 PR 07-DEC-1999; 99US-169495P.
 PR 15-NOV-2001; 2001US-0002796.
 XX
 PA (GETH) GENENTECH INC.
 XX
 PI Ashkenazi AJ, Baker KP, Botstein DA, Desnoyers L, Eaton DL,
 PI Ferrara N, Fong S, Gao W, Geisler H, Gerritsen ME, Goddard A;
 PI Godowski PJ, Gurney AL, Kljavin IJ, Mather JP, Napier MA, Pan J;
 PI Paoni NF, Roy MA, Stewart TA, Tumas D, Watanabe CK, Williams PM;
 PI Wood WI, Zhang Z;
 XX WPI; 2003-328482/31.
 DR N-PSDB; ACA60494.
 DR
 XX
 PT Novel secreted and transmembrane polypeptide for modulating biological
 PT activity of cell expressing the polypeptide, for identifying agonists
 PT or antagonists of polypeptide, and as molecular weight markers -
 PT
 PS Claim 12; Fig 34; 254pp; English.
 XX
 CC The invention describes an isolated, secreted and transmembrane
 CC polypeptide (PP), termed PRO PP or fibroblast growth factor receptor PP
 CC (I). (I) is useful for detecting PRO533, PRO301, PRO187, PRO337,
 CC PRO1411, PRO10096, PRO246, PRO6307, PRO6003, fibroblast growth factor
 CC receptor (FGFR)-3, FGFR-4, FGFR-1, FGFR-2, PRO6004, PRO4356, PRO2630,
 CC PRO265 or PRO951 polypeptide, and for linking a bioactive molecule to a
 CC cell expressing the above polypeptides. The bioactive molecule, a toxin,
 CC radiolabel or an antibody, causes cell death. PRO is useful in assays to
 CC identify other proteins or molecules involved in binding interaction.
 CC The polynucleotide (II) encoding (I) is useful in chromosome and gene
 CC mapping, in generation of antisense RNA and DNA, for generating
 CC transgenic animals or knockout animals which in turn are useful in the
 CC development and screening of therapeutically useful reagents, to
 CC construct hybridisation probes for mapping the gene which encodes the

Db 181 DGPHPVITPRASASSDGPHPVITPRASASSDGPHPVITPRASASSDGP 240
Qy 222 HVPITPSGSDVTLAEALVTNINIEVINGSIETETSSICASDIDLIPTEGVKA 281
Db 241 HVPITPSGSDVTLAEALVTNINIEVINGSIETETSSICASDIDLIPTEGVKA 300
Qy 282 SSTSPPALPDSTAKPHITEVTAETLSTAGTTESAAPHATVGTPTPTNSATREVT 341
Db 301 SSTSPPALPDSTAKPHITEVTAETLSTAGTTESAAPDATIGTPTPTNSTIEREY 360
Qy 342 PGATTLISGALVTVSRNPLEETSALSVETPSYKVSAAAPVSTEAGSAVKTTSPAGSS 401
Db 361 PGATTLISGALVTVSRNPLEETSALSVETPSYKVSAAAPVSTEAGSAVKTTSPAGSS 418
Qy 402 SYSPSEAAKNFTPTSETPTMDIATKGPFTSRDPLPSVPTTNSRGNTSLAKITTS 461
Db 419 SYSPSEAAKNFTPTSETPTMDIATKGPFTSRDPLPSVPTTNSRGNTSLAKITTS 478
Qy 462 KTKMPQQRPLPGRGRPT 482
Db 479 KTKMPPTATP-TTARTREPT 498
RESULT 2
092718
ID Q9P218 PRELIMINARY; PRT; 517 AA.
AC Q9P218;
DT 01-OCT-2000 (TrEMBLrel. 15, Created)
DT 01-OCT-2000 (TrEMBLrel. 15, Last sequence update)
DT 01-OCT-2002 (TrEMBLrel. 22, Last annotation update)
DE Hypothetical protein KIAA1359 (Fragment).
GN KIAA1359
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
OX NCBI_TaxID=9606;
RN [1]
RP SEQUENCE FROM N.A.
RC TISSUE=Brain;
RX MEDLINE=20181126; PubMed=10718198;
RA Nagase T., Kikuno R., Ishikawa K., Hirokawa M., Ohara O.;
RT "Prediction of the coding sequences of unidentified human genes.XVI.
RT The complete sequences of 150 new cDNA clones from brain which code
RT for large proteins in vitro.";
RL DNA Res 7:65-73(2000).
DR EMBL; AB037780; BAA92597.1; -
KW Hypothetical protein.
FT NON TER 1
SQ SEQUENCE 517 AA; 52332 MW; 6D14ABA896221DFF CRC64;

Query Match 88.4%; Score 2146.5; DB 4; Length 517;
Best Local Similarity 87.5%; Pred. No. 1.2e-108;
Matches 439; Conservative 2; Mismatches 4; Indels 57; Gaps 1;
Qy 23 SSAGPSTRADTAMTDDTEVPAMTAPGHALETQTLAETSSRSTPAGPIPEATRG 82
Db 13 TNGPSTRADTAMTDDTEVPAMTAPGHALETQTLAETSSRSTPAGPIPEATRG 72
Qy 83 AKRISARETRSTKTSNPNMVLIAVSETSASGSGPEGGMVTTQITGSDPEAIPT 142
Db 73 AKRISARETRSTKTSNPNMVLIAVSETSASGSGPEGGMVTTQITGSDPEAIPT 132
Qy 143 LCTDDSEAKTITMDILTLAHTSTBAKGLS----- 173
Db 133 LCTDDSEAKTITMDILTLAHTSTBAKGLSSESSASSDGPHPVITPRASASSDGP 192
Qy 174 -----SSSSASSDGPHPVITPRASASSASSDGP 205
Db 193 HPVITPRASASSASSDGLHPVITPRASASSASSDGPHPVITPRASASSASSDGP 252
Qy 206 ITPRASASSASSDGPHPVITPSWPGSDVTLAEALVTNINIEVINGSIETETSS 265
Db 253 ITPRASASSASSDGPHPVITPSWPGSDVTLAEALVTNINIEVINGSIETETSS 312

Tue Jan

Qy 266 PGASDIDLIPTEGVKASSTSDPPALPDSTAKPHITEVTAETLSTAGTTESAAPHATV 325
Db 313 PGASDIDLIPTEGVKASSTSDPPALPDSTAKPHITEVTAETLSTAGTTESAAPHATV 372
Qy 326 GTPLPTNSATERVTPAGATTLISGALVTVSRNPLEETSALSVETPSYKVSAAAPV 385
Db 373 GTPLPTNSATERVTPAGATTLISGALVTVSRNPLEETSALSVETPSYKVSAAAPV 432
Qy 386 GSAVGKTTSPAGSSASSYSPSEAAKNFTPTSETPTMDIATKGPFTSRDPLPSVPTT 445
Db 433 GSAVGKTTSPAGSSASSYSPSEAAKNFTPTSETPTMDIATKGPFTSRDPLPSVPTT 492
Qy 446 SSRGTNSTLAKITTSKTTMKP 467
Db 493 SSRGTNSTLAKITTSKTTMKP 514
RESULT 3
Q96KAI PRELIMINARY; PRT; 487 AA.
AC Q96KAI;
DT 01-DEC-2001 (TrEMBLrel. 19, Created)
DT 01-DEC-2001 (TrEMBLrel. 19, Last sequence update)
DT 01-MAR-2003 (TrEMBLrel. 23, Last annotation update)
DE Hypothetical protein FLJ14408.
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
OX NCBI_TaxID=9606;
RN [1]
RP SEQUENCE FROM N.A.
RC TISSUE=Embryo;
RA Isogai T., Oca T., Hayashi K., Sugiyama T., Otsuki T., Suzuki Y.,
RA Nishikawa T., Nagai K., Sugano S., Shiratori A., Sudo H., Sugawara M.,
RA Wagatsuma M., Hosoi T., Kaku Y., Kodaira H., Kondo H., Takiguchi S.,
RA Takahashi M., Chiba Y., Ishida S., Murakawa K., Ono Y., Takiguchi S.,
RA Watanabe S., Kimura K., Murakami K., Ishii S., Kawai Y., Saito K.,
RA Yamamoto J., Wakamatsu A., Nakamura Y., Nagahara K., Masubo Y.,
RA Ninomiya K., Iwayanagi T.;
RT "NSD human cDNA sequencing project.";
RL Submitted (May-2001) to the EMBL/GenBank/DBJ databases.
DR EMBL; AK027314; BAB55035.1; -
KW Hypothetical protein.
SQ SEQUENCE 487 AA; 50120 MW; 6A60F56465875886 CRC64;

Query Match 84.8%; Score 2060; DB 4; Length 487;
Best Local Similarity 87.1%; Pred. No. 5.2e-104;
Matches 420; Conservative 0; Mismatches 10; Indels 52; Gaps 2;
Qy 1 MGCLWGLALPLFFFCWEVGVSGSAGSTRRADTAMTDDTEVPAMTAPGHALETQTL 60
Db 1 MGCLWGLALPLFFFCWEVGVSGSAGSTRRADTAMTDDTEVPAMTAPGHALETQTL 60
Qy 61 SAETSSRSTPAGPIPEATRGAKRISAPARETSFRTKSNFMVLIAVSETSASGSP 120
Db 61 SAETSSRSTPAGPIPEATRGAKRISAPARETSFRTKSNFMVLIAVSETSASGSP 120
Qy 121 GAGMTTQITGSDPEAIPTLCTDDSEAKTITMDILTLAHTSTBAKGLSSESSASS 180
Db 121 GAGMTTQITGSDPEAIPTLCTDDSEAKTITMDILTLAHTSTBAKGLSSESSASS 180
Qy 181 DGPHPVITPRASASSASSDGPHPVITPRASASSASSDGPHPVITPSWPGSDVTLAE 240
Db 181 DGPHPVITPRASASSASSDGPHPVITPRASASSASSDGPHPVITPSWPGSDVTLAE 240
Qy 241 ALVTNINIEVINGSIETETSSICASDIDLIPTEGVKASSTSDPPALPDSTAKPHI 300
Db 241 ALVTNINIEVINGSIETETSSICASDIDLIPTEGVKASSTSDPPALPDSTAKPHI 300
Qy 301 TEVTASAEITLSTAGTTESAAPHATVGTPTPTNSATREVTAPGATTLISGALVTVSRNPLE 360
Db 301 TEVTASAEITLSTAGTTESAAPHATVGTPTPTNSATREVTAPGATTLISGALVTVSRNPLE 360